Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

92008

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents have been recorded by the NHS of Citalopram leading to the deterioration of a patient's health in the last five years.
tabling member constituency	Richmond Park
tabling member printed	Zac Goldsmith
uin	209345
answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the Yellow Card Scheme.</p><p> </p><p><strong> </strong></p><p> </p><p>The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a doctor or patient suspects may have been due to a medicine. The MHRA has received a total of 1207 suspected ADR reports in association with citalopram between 1 January 2009 and 31 August 2014. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs. The number of reports received directly from the NHS cannot be determined.</p><p> </p><p> </p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/10/2014 16:18:40 answering member 4020 label Biography information for George Freeman
tabling member	4062 label Biography information for Lord Goldsmith of Richmond Park

91470

registered interest
date	10/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of trends in the prescribing of anti-depressants during the recent recession.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	209039
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>The particular indication that a medicine is prescribed for is not known. Information on the number of prescription items indicated for anti-depressant dispensed in the community since 1991, as defined in the British National Formulary (BNF) section 4.3 Anti-depressant Drugs. is shown in the following table. The number of prescription items dispensed per 100,000 population is also provided for context.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Antidepressant prescription items dispensed in the community in England and items per 100,000 population</p></td></tr><tr><td><p>Year</p></td><td><p>Prescription items</p></td><td><p>Items per 100,000 population</p></td></tr><tr><td><p>1991</p></td><td><p>8,953,900</p></td><td><p>18,703</p></td></tr><tr><td><p>1992</p></td><td><p>9,914,330</p></td><td><p>20,656</p></td></tr><tr><td><p>1993</p></td><td><p>10,776,690</p></td><td><p>22,404</p></td></tr><tr><td><p>1994</p></td><td><p>11,816,438</p></td><td><p>24,501</p></td></tr><tr><td><p>1995</p></td><td><p>13,227,137</p></td><td><p>27,338</p></td></tr><tr><td><p>1996</p></td><td><p>14,960,610</p></td><td><p>30,834</p></td></tr><tr><td><p>1997</p></td><td><p>16,822,563</p></td><td><p>34,568</p></td></tr><tr><td><p>1998</p></td><td><p>18,424,473</p></td><td><p>37,739</p></td></tr><tr><td><p>1999</p></td><td><p>20,108,130</p></td><td><p>41,009</p></td></tr><tr><td><p>2000</p></td><td><p>22,021,840</p></td><td><p>44,730</p></td></tr><tr><td><p>2001</p></td><td><p>24,342,713</p></td><td><p>49,227</p></td></tr><tr><td><p>2002</p></td><td><p>26,329,382</p></td><td><p>52,999</p></td></tr><tr><td><p>2003</p></td><td><p>27,657,990</p></td><td><p>55,399</p></td></tr><tr><td><p>2004</p></td><td><p>28,995,511</p></td><td><p>57,766</p></td></tr><tr><td><p>2005</p></td><td><p>29,389,874</p></td><td><p>58,076</p></td></tr><tr><td><p>2006</p></td><td><p>31,037,983</p></td><td><p>60,900</p></td></tr><tr><td><p>2007</p></td><td><p>33,839,594</p></td><td><p>65,860</p></td></tr><tr><td><p>2008</p></td><td><p>35,960,539</p></td><td><p>69,401</p></td></tr><tr><td><p>2009</p></td><td><p>39,140,459</p></td><td><p>74,987</p></td></tr><tr><td><p>2010</p></td><td><p>42,787,966</p></td><td><p>81,280</p></td></tr><tr><td><p>2011</p></td><td><p>46,677,813</p></td><td><p>87,894</p></td></tr><tr><td><p>2012</p></td><td><p>50,167,201</p></td><td><p>93,781</p></td></tr><tr><td><p>2013</p></td><td><p>53,326,550</p></td><td><p>98,999</p></td></tr><tr><td colspan="3"><p>Sources: Office of National Statistics and Prescription Cost Analysis provided by the Health and Social Care Information Centre</p></td></tr></tbody></table><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:52:51 answering member 4020 label Biography information for George Freeman
tabling member	534 label Biography information for Chris Ruane

62324

registered interest
date	17/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answer of 19 January 2012, Official Report, columns 932-3W, how many companies hold licences for the manufacture or distribution of (a) Nitrazepam, (b) Flurazepam, (c) Loprazolam, (d) Lormetazepam, (e) Temazepam, (f) Clonazepam, (g) Medazepam, (h) Midazolam, (i) Zopiclone, (j) Zaleplon, (k) Zolpiden, (l) Eszopiclone, (m) SSRI antidepressants and (n) trycyclic antidepressants; and how many of those licences were issued in the last three years.
tabling member constituency	Heywood and Middleton
tabling member printed	Jim Dobbin
uin	201050
answer	answer is ministerial correction date of answer 23/06/2014 answer text <p>There are currently 15 products authorised in the United Kingdom containing nitrazepam and 15 different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently two products authorised in the UK containing flurazepam and one company authorised to manufacture and distribute them.</p><p> </p><p>There are currently two products authorised in the UK containing loprazolam and two different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently eight products authorised in the UK containing lormetazepam and four different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently 10 products authorised in the UK containing temazepam and six different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently six products authorised in the UK containing clonazepam and three different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently no authorised products in the UK containing medazepam.</p><p> </p><p>There are currently 22 products authorised in the UK containing midazolam and 10 different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently 17 products authorised in the UK containing zopiclone and nine different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently two products authorised in the UK containing zaleplon and one company authorised to manufacture and distribute them.</p><p> </p><p>There are currently 21 products authorised in the UK containing zolpidem and 12 different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently no authorised products in the UK containing eszopiclone.</p><p> </p><p>There are currently 238 products authorised in the UK containing SSRI antidepressants and 57 different companies authorised to manufacture and distribute them.</p><p> </p><p>There are currently 16 products authorised in the UK containing tricyclic antidepressants and 11 different companies authorised to manufacture and distribute them.</p><p> </p><p>One loprazolam, four lormetazepam, two clonazepam, two midazolam, three zopiclone, four zolpidem and 75 SSRI products have been authorised in the last three years.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 23/06/2014 15:15:27 answering member 1439 label Biography information for Norman Lamb
tabling member	446 label Biography information for Jim Dobbin